Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

“…A reasonable question arising from these observations is whether or not rituximab combined with more intensive chemotherapy would further improve the already impressive results achieved using R-CHOP. In a recent study, R-MACOP-B provided very good results, which, however, did not appear to be better than expected with MACOP-B alone [5][6][7]9] when both were combined with RT [43]. In another report, wherein R-VACOP-B appeared to be superior to VACOP-B alone, both without RT, the long-term FFS rate for the former was 84% [44].…”

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

“…[17][18][19][20][21][22]27,35 HDT/ASCT and 2 nd -/3 rd -generation regimens that were more intensive and that have been historically used as first-line treatment for PMBL resulted in better outcomes than those seen in response to CHOP chemotherapy. 11,17,18,36 In the present study, similar OS and PFS was observed among patients treated with a 2 nd -/3 rd -generation regimen, HDT/ASCT, and R-CHOP. This suggests that R-CHOP regimen might have curative potential in a significant proportion of PMBL patients without utilizing 2 nd -/3 rd -generation regimen or HDT/ASCT and thereby avoiding their associated toxicities.…”

“…[13][14][15][16][17][18][19][20][21][22] In the literature, more than 80% of patients with PMBL receiving immunochemotherapy with or without radiotherapy (RT) also achieved longterm overall survival (OS). [17][18][19][20][21][22] Despite the outstanding advances with R-CHOP, 20%-30% of patients still experience progression or relapse and have poor outcomes. Moreover, approximately 80% of long-term survivors treated with R-CHOP required consolidative RT for residual mediastinal disease.…”

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

“…Response after R-CT and after RT was evaluated on CT scans, 18 FDG-PET scans, or both by using the 2007 revised response criteria for malignant lymphomas: complete response (CR), regression to normal size on CT or mass of any size if 8 FDG-PET result was negative; partial response (PR), ≥50% decrease in the sum of the products of the diameters of up to 6 largest dominant masses, no increase in size of other nodes, or 1 or more 8 FDG-PET positive results at previously involved site (12).…”